These results suggest that ZEB2‐expressing CRC cells acquire resistance to chemotherapeutic agents commonly used in CRC treatment and may explain the observed reduced survival in patients with ZEB2‐positive tumours who received FOLFOX chemotherapy despite inducing a partial EMT. The gene discussed is ZEB2; the disease is colorectal carcinoma.